Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Anti-epilepsy drug risk on cognitive function for unborn children

Anti-epilepsy drug risk on cognitive function for unborn children

July 22, 2009

Interim results of a study being conducted by scientists at the University of Liverpool suggest that children aged three years and younger, who are born to women taking the anti-epileptic drug sodium valproate whilst pregnant, are likely to have an IQ of six to nine points lower than average.

The research, in collaboration with Emory University in the US and the Central Manchester University Hospitals NHS Foundation Trust, tested more than 300 three-year-olds in the UK and US, whose mothers took one of four anti-epilepsy drugs (AEDs) whilst pregnant. The preliminary findings suggest that children exposed to the drug sodium valproate had lower IQ results than children exposed to other AEDs, regardless of the mother's IQ. The results also took dosage, duration of pregnancy and mother's consumption of folic acid whilst pregnant, into account.




Professor of Clinical Neuropsychology at the University, Gus Baker, said "Our research looked at how exposure to sodium valproate and other AEDs in the womb affected children's everyday life - in particular their IQ, memory and language abilities from one to six years of age."

Around 5,000 women with epilepsy become pregnant every year in the UK and the majority of these, including those on AEDs, will experience uncomplicated pregnancies and births. Previous research conducted by the team has already shown that children exposed to AEDs such as sodium valproate in the womb are more likely to suffer birth defects characterised by heart malformations, dysmorphic features and minor limb deformities.

Professor Baker added: "The answer is not as simple as to take women off AEDs altogether as the effects of suffering a seizure can also pose a risk for both mother and unborn child. It is vital that the research is now used to educate women with epilepsy before they start to plan for a family. Women need to be aware of the risks so that they can make informed choices with the help and advice of experts. It is also important that women do not stop taking AED treatment without taking advice from their medical practitioner."

"It is important to stress that sodium valproate is used globally and it has a favourable safety profile for all adult patients who use it. It has a range of pharmaceutical uses including bipolar disorder, migraine, epilepsy, and in adults sodium valproate is extremely effective."

University of Liverpool



Related Sodium Valproate Current Events and Sodium Valproate News Articles
Suspected fatal side effects of drugs in children have risen over past decade
The number of suspected fatal side effects from drugs prescribed to children and reported to the UK’s drugs early warning system, has risen over the past decade, shows research in the Archives of Disease in Childhood.
More Sodium Valproate Current Events and Sodium Valproate News Articles
  Fourth International Symposium on Sodium Valproate and Epilepsy
by Royal Society of Medicine Services (Publisher)



  Therapeutic Monitoring of Antiepileptic Drugs: Clinical Pharmacokinetic Aspects of Carbamazepine and Sodium Valproate and their Interaction with other Antiepileptic Drugs
by Svein I. Johannessen (Author)



  In utero sodium valproate exposure linked to higher risk of autism.(News): An article from: OB GYN News
by Elizabeth Mechcatie (Author)

This digital document is an article from OB GYN News, published by International Medical News Group on December 15, 2008. The length of the article is 726 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: In utero sodium valproate exposure linked to higher risk of autism.(News)
Author: Elizabeth Mechcatie
Publication: OB GYN News (Magazine/Journal)
Date: December 15, 2008
Publisher: International Medical News Group
Volume: 43 Issue: 24 Page: 2(1)

Distributed by Gale, a part of Cengage...

  The Place of sodium valproate in the treatment of epilepsy (International congress and symposium series - [Royal Society of Medicine ; no. 30)
by Grune & Stratton (Publisher)



  The Place of Sodium Valproate in the Treatment of Epilepsy (Royal Society of Medicine International Congress and Symposium Ser., No. 30)
by M. J. (editor); Caldwell, A. D. (editor) Parsonage (Author)



  Pharmacokinetics and metabolism of the antiepileptic drug sodium valproate (Depakine, Epilim): Proceedings of a workshop
by Bohn, Scheltema & Holkema (Publisher)



  A critical study of information flow and processing of adverse drug reactions with the example of sodium valproate, an anticonvulsant drug
by R. C Thapliyal (Author)



  Clinical and Pharmacological Aspects of Sodium Valproate (Epilin) in the Treatment of Epilepsy: Symposium Proceedings
by N.J. Legg (Editor)



  Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy: Proceedings of a symposium held at Nottingham University, 23-24 September, 1975
by MCS Consultants for Reckitt-Labaz (Publisher)



  THE PLACE OF SODIUM VALPROATE IN THE TREATMENT OF EPILEPSY (INTERNATIONAL CONGRESS AND SYMPOSIUM SERIES - [ROYAL SOCIETY OF MEDICINE ; NO. 30)
by Unknown (Author)



© 2009 BrightSurf.com